Atea Pharmaceuticals Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _______________ to _______________Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (857) 284-8891(Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reportingcompany☒Emerging growthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 11, 2026, the registrant had 80,027,099 shares of common stock, $0.001 par value per share, outstanding. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements. We make such forward-looking statementspursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federalsecurities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead,they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plansand strategies, our clinical development timelines and results and other future conditions. The words “aim,” “anticipate,”“believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” "objective," "on track," “plan,”“possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” or the negative of these terms or othersimilar expressions are intended to identify forward-looking statements, although not all forward-looking statementscontain these identifying words. These forward-looking statements include, among other things, statements about: •our expectations relating to clinical trials for our hepatitis C virus (“HCV”) and hepatitis E virus ("HEV")product candidates and any other potential product candidates, including projected costs, study designs andthe timing for initiation, recruitment, completion, and reporting interim, top-line and final results;•the potential therapeutic benefit of our HCV and HEV product candidates and market opportunities therefor;•the safety profile and related adverse events of our HCV and HEV product candidates;•our plans to research, develop and commercialize our current and future product candidates;•the potential benefits of any future collaboration we may enter into;•the timing of and our ability to apply for, and if successful, obtain and maintain regulatory approvals for ourproduct candidates;•the expected size of the commercial market for our HCV and HEV product candidates and any other productcandidate for which we may receive marketing approval;•the rate and degree of market acceptance and clinical utility of any products for which we may receivemarketing approval;•our manufacturing and commercialization capabilities and strategy;•our estimates regarding future revenue, expenses and results of operations;•the progress of, timing of and amount of expenses associated with our research, development andcommercialization activities;•our future financial position, capital requirements, cash runway, needs for additional financing and theavailability of such financing;•our business strategy and review of strategic alternatives;•developments relating to our industry and our competitors, inc